• [[ Whitepaper ]] Connecting With Rare Disease Patient Communities: Patient Advocates

    laureng Whitepapers April 19, 2018
  • [[Whitepaper ]] Disruptive Innovation in Rare Disease Markets

    laureng Whitepapers April 19, 2018
  • Choosing the Right Channel Strategy for Specialty Product Success

    Karina Kusova Clinical Development, Market Access, Orphan Drug Congress, Supply Chain & Manufacturing, Uncategorized, Whitepapers May 3, 2017
  • [Whitepaper] Challenging Conventional Patient Recruitment and Care Strategies for Rare Disease Studies

    Karina Kusova Clinical Development, Orphan Drug Congress, Uncategorized, Whitepapers April 10, 2017
  • [[whitepaper]] The New Reality: Maximizing Value in Rare Disease Launches

    Karina Kusova Clinical Development, Featured on App, Orphan Drug Congress, Uncategorized, Whitepapers April 6, 2017
  • What’s New in Rare Cancer Research? (Spoiler Alert: A Lot!)

    Karina Kusova Advocacy, Clinical Development, Market Access, Orphan Drug Congress, Orphan Drugs Live October 10, 2016

Subscribe to Total Orphan Drugs

Strategy and innovation in the orphan drugs and rare diseases industry
Navigation
  • Development
  • Regulation
  • Advocacy
  • Market Access
  • Partnering & Investment
  • Whitepapers
  • Events
    • USA
  • Search
epilepsy

Tag Archive

View Post

SAGE Therapeutics Presents New Preclinical Data on SAGE-217 at Eilat Conference on New Anti-Epileptic Drugs

In Press Release by CameronSeptember 8, 2014Leave a Comment

Data Highlight Potential of SAGE-217 to Address Acute and Chronic Forms of Epilepsy and Seizure Disorders September 2, 2014 SAGE Therapeutics today presented preclinical data …

View Post

Insys Therapeutics Receives FDA Orphan Drug Designation for Its Pharmaceutical Cannabidiol as a Potential Treatment for Dravet Syndrome, a Rare Form of Epilepsy

In Press Release by CameronJuly 7, 2014Leave a Comment

July 2, 2014 Insys Therapeutics, Inc., a specialty pharmaceutical company that is developing and commercializing innovative drugs and novel drug delivery systems, today announced that …

View Post

Insys Therapeutics Receives FDA Orphan Drug Designation for Its Pharmaceutical Cannabidiol as a Potential Treatment for Rare Form of Epilepsy, Lennox-Gastaut Syndrome

In Press Release by CameronJune 30, 2014Leave a Comment

June 25, 2014 Insys Therapeutics, Inc., a specialty pharmaceutical company that is developing and commercializing innovative drugs and novel drug delivery systems, today announced that …

View Post

FDA Issues Complete Response Letter for PLUMIAZ™, Investigational Medicine for Epilepsy Cluster Seizures

In Press Release by CameronMay 2, 2014Leave a Comment

Acorda Therapeutics Committed to Working with FDA May 2nd, 2014 Acorda Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has issued …

View Post

Courtagen to Provide Genetic Profiling of Children with Intractable Epilepsy to Support Clinical Developments with Cannabidiol

In Press Release by CameronApril 4, 2014Leave a Comment

Using the latest next-generation sequencing technologies, Courtagen is collaborating with various academic centers and US physicians to profile the genomes of intractable epilepsy patients to …

Lundbeck receives FDA approval for Epilepsy Intravenous Carbamazepine

In Press Release by CameronMarch 10, 2014Leave a Comment

FDA Accepts Lundbeck Submission of New Drug Application for Intravenous Carbamazepine March 10, 2014 Lundbeck LLC today announced that the U.S. Food and Drug Administration …

Categories

  • Advocacy
  • Clinical Development
  • Featured on App
  • Market Access
  • Orphan Drug Congress
  • Orphan Drugs Live
  • Partnering & Investment
  • Press Release
  • Regulation & Government
  • Reports
  • Supply Chain & Manufacturing
  • Uncategorized
  • Whitepapers
Toggle the Widgetbar
World Orphan Drug Congress USA
  • Home
  • About Us/Advertise